Search results for "Important Difference"
showing 3 items of 23 documents
Cervical Disc Arthroplasty -Efficacy and Indications. Single Center Long-Term Cohort Study Compared to Rcts’ Results
2019
Purpose: This study aims to compare CTDR and ACDF functional outcomes and to determine whether our criterion to exclude patient from the CTDR cohort positively affects the results. Methods: We have conducted a single-center, prospective, observational study of two cohorts: CTDR n=88, and ACDF n=90. The choice of the method for the particular patient was not fully random – it depended on the assumed disqualification criterion for CTDR the lack of intra-operatively determined mobility. Both cohorts were clinically followed over the long-term (average: 8 years). Our results were summarized with the results of large randomized studies subjected by our team to a meta-analysis reported in full in…
Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea…
2021
Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA) that resolves under treatment with continuous positive airway pressure (CPAP). In some patients, sleepiness persists despite CPAP treatment. We retrospectively analyzed data on subjective residual EDS, assessed as an Epworth Sleepiness Scale score (ESS) >10, in patients from the European Sleep Apnea Database (n = 4,853, mean age +/- SD 54.8 +/- 11.8 years, 26.1% females), at baseline and at the first visit (median follow-up: 5 months, interquartile range 3-13). An ESS > 10 occurred in 56% of patients at baseline and in 28.2% of patients at follow-up. Residual EDS was analyzed in 2,190 patients (age: 55.1 +/- 12…
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…
2014
Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…